A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

Trial Profile

A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms IMspire170
  • Sponsors Roche
  • Most Recent Events

    • 29 Sep 2017 Last checked against ClinicalTrials.gov record
    • 01 Sep 2017 Status changed from planning to not yet recruiting.
    • 20 Jul 2017 This trial is expected to begin in the third quarter of 2017, according to an Exelixis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top